Richter to market HRA Pharma prods

Hungarian drug major Richter Gedeon has entered into an agreement to market and distribute Paris, France-based HRA Pharma's product  ella/ellaOne in Central Eastern Europe and the Commonwealth of  Independent States, enabling women in these areas to have greater  control over their own contraception.

HRA Pharma will supply the products to Richter for commercialization in  seven CEE countries (Bulgaria, Czech Republic, Hungary, Poland, Romania,  Serbia and Slovakia) and the 12 CIS nations (Azerbaijan, Armenia,  Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikistan,  Turkmenistan, Uzbekistan and Ukraine). Developed by HRA Pharma,  ella/ellaOne is an innovative, next-generation emergency contraceptive  based on the new chemical entity ulipristal acetate. The product is  still undergoing evaluation by health authorities and is awaiting  regulatory approvals. No financial terms of the deal were disclosed.

The companies claim that the collaboration combines complementing  industry expertise and regional strengths. HRA Pharma is a pioneer in  the design and development of products in reproductive health. Richter  is the CEE's leading pharmaceutical manufacturing group, with a direct  presence in 30 countries, 14 commercial subsidiaries and wholesalers and  four manufacturing sites. As recognized players in the emergency  contraceptive field, this agreement allows both companies the  opportunity to offer women a greater choice in terms of contraceptive  solutions.